Clinical Study
Response to Initial Therapy of Differentiated Thyroid Cancer Predicts the Long-Term Outcome Better than Classical Risk Stratification Systems
Table 3
Clinical endpoints for each risk stratification system.
| | | ETA | ATA | RIT | | | Low
() | High
() | Low
() | Intermediate
() | High
() | Excellent
() | Acceptable
() | Incomplete
() |
| | No evidence of disease after initial therapy | 87.9% (87) | 51.9% (40) | 91.8% (90) | 51.4% (36) | 12.5% (1) | 97.7% (125) | 10.5% (2) | 0% (0) |
| | No evidence of disease after additional therapy | 6.1% (6) | 7.8% (6) | 3.1% (3) | 11.4% (8) | 12.5% (1) | 0% (0) | 21.1% (4) | 27.6% (8) |
| | Persistent biochemical disease | 5.1% (5) | 26% (20) | 4.1% (4) | 25.7% (18) | 37.5% (3) | 2.3% (3) | 63.2% (12) | 34.5% (10) |
| | Persistent structural disease | 1% (1) | 11.7% (9) | 1% (1) | 11.4% (8) | 12.5% (1) | 0% (0) | 5.3% (1) | 31% (9) |
| | Disease specific mortality | 0% (0) | 2.6% (2) | 0% (0) | 0% (0) | 25% (2) | 0% (0) | 0% (0) | 6.9% (2) |
|
|
